الفهرس 
IntroductionOnly 14 pages are availabe for public view
 |  | from | 134 |  |  |
| | | from | 134 | | |
Abstract
SUMMARY AND CONCLUSION Iron deficiency anemia affects an estimated 1–2 billion people worldwide. In developing countries, over 50% of pregnant women are anemic, 46–66% of children under 4 years old are anemic, with one-half attributed to iron deficiency. Ischemia-modified albumin (IMA), a marker of oxidative stress, increases in conditions such as hypoxia, acidosis and free radical damage. Human serum albumin, a single chain of 585 amino acids, consists of three structurally homologous, largely helical domains (I, II, and III), each domain consists of two subdomains, A and B. Recent studies have determined that serum IMA levels increase in several ischemic states including iron deficiency anemia, acute coronary syndrome, ischemic central nervous system disease, lower extremity ischemia and pulmonary embolism.The amount of iron must remain in balance in the body. Iron also plays a role in the occurance of oxidative damage. The oxidative free radicals during ischemia lead to chemical changes in the albumin molecule and IMA may be the earliest marker of ischemia. The aim of this study is to measure the level of IMA in patients with iron deficiency anemia before and after iron supplementation therapy and to spot light on its correlation with severity of anemia and to asses clinical outcomes after iron therapy with respect to oxidative stress.The study was carried out on (50) subjects divided onto two groups as fellow : group I: Twenty healthy subjects as a control with no history of iron deficiency anemia.